Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 17/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 17/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35086 | 0.91 | NR1H2 (0.58) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL35158 | 0.89 | NR1H2 (0.55) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL35209 | 0.88 | MAPT (0.47) | SMN1; SMN2NR1H2NR1H3MAPTLMNA | |
| SCHEMBL35835 | 0.88 | NR1H2 (0.50) | SMN1; SMN2NPC1RAB9AKMT2ANR1H2 | |
| SCHEMBL35356 | 0.85 | NR1H2 (0.51) | MEN1RAB9AKMT2ANR1H2NR1H3 | |
| SCHEMBL45918 | 0.85 | NR1H2 (0.50) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL35085 | 0.84 | NR1H2 (0.58) | SMN1; SMN2NR1H2NR1H3MAPTLMNA | |
| SCHEMBL35310 | 0.81 | NR1H2 (0.55) | NR1H2NR1H3 | |
| SCHEMBL35160 | 0.80 | NR1H2 (0.59) | NR1H2NR1H3 | |
| SCHEMBL35004 | 0.80 | NR1H3 (0.52) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | NR1H2, NR1H3, NR1H4 | SMN1; SMN2 4218/4885MEN1 3801/4885NPC1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.